All In Biotech

Drug Trial Radar · NCT04509674

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction

Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 6,522 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,522

Actual

Start

Dec 16, 2020

Primary completion

Nov 5, 2023

Study completion Nov 5, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Aug 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying from cardiovascular disease. People who are in hospital may join the study soon after being treated for their heart attack. Participants are put into 2 groups by chance. One group takes 1 empagliflozin tablet a day. The other group takes 1 placebo tablet a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine. All participants continue their standard treatment. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. Empagliflozin is a medicine that helps people with type 2 diabetes to lower their blood sugar. Researchers think that empagliflozin might also help people after heart attack who are at risk for heart failure, whether or not they have diabetes. Participants are in the study for about 1 to 2 years. During this time, there are about 4 visits inperson, 2 visits are done either by phone or by use of an mobile application. Results between the empagliflozin and placebo groups are compared. The doctors also regularly check the general health of the participants.

Conditions

  • Myocardial Infarction

Interventions

  • EmpagliflozinDrug

    Empagliflozin

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of Time to First Heart Failure Hospitalisation or All-cause MortalityTime frame: From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.

Locations

439 sites in 22 countries. Site status is shown where the registry gives one.

  • Advanced Cardiovascular LLC

    Alexander City, Alabama

  • Grandview Medical Center

    Birmingham, Alabama

  • Heart Center Research, LLC

    Huntsville, Alabama

  • Mercy Gilbert Medical Center

    Gilbert, Arizona

  • Arkansas Cardiology, PA

    Little Rock, Arkansas

  • Comprehensive Cardiovascular Medical Group

    Bakersfield, California

  • Valley Clinical Trials, Inc.

    Covina, California

  • Cardiovascular Innovation and Research Center

    Long Beach, California

  • University of California Los Angeles

    Los Angeles, California

  • InvivoCure

    Mission Hills, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Valley Clinical Trials, Inc.

    Pasadena, California

  • Kaiser Permanente

    San Diego, California

  • San Diego Cardiac Center

    San Diego, California

  • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Interventional Cardiology Medical Group

    West Hills, California

  • George Washington University Medical Faculty Associates

    Washington D.C., District of Columbia

  • Clearwater Cardiovascular Consultants

    Clearwater, Florida

  • Integrative Research Associates

    Fort Lauderdale, Florida

  • University of Florida Health Jacksonville

    Jacksonville, Florida

  • Cardiology Partners Clinical Research Institute

    Palm Beach Gardens, Florida

  • Charlotte Heart Group Research Center

    Port Charlotte, Florida

  • Grady Memorial Hospital

    Atlanta, Georgia

  • Cardiovascular Consultants of South Georgia, LLC

    Thomasville, Georgia

  • Atlanta Heart Specialists, LLC

    Tucker, Georgia

  • Advanced Heart Care, LLC, Medicoricum, LLC

    Fairview Heights, Illinois

  • Midwest Cardiovascular Research and Education Foundation

    Elkhart, Indiana

  • Cardiovascular Research of Northwest Indiana, LLC

    Munster, Indiana

  • Reid Physician Associates

    Richmond, Indiana

  • Midwest Heart and Vascular Specialists

    Overland Park, Kansas

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • University of Louisville

    Louisville, Kentucky

  • Eastern Maine Medical Center

    Bangor, Maine

  • Cardiovascular Specialists of Central Maryland

    Columbia, Maryland

  • Shady Grove Adventist Hospital

    Rockville, Maryland

  • Healthy Heart Cardiology

    Grand Rapids, Michigan

  • Western Michigan University

    Kalamazoo, Michigan

  • Mid Michigan Medical Center

    Midland, Michigan

  • Michigan Heart, PC

    Ypsilanti, Michigan

  • Minneapolis Heart Institute Foundation

    Minneapolis, Minnesota

Showing 40 of 439 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.